24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 689 participants.
Also called NCT02243176
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 689 participants
- Sponsor
- Registry
-
NCT02243176
-
- Other papers using this trial's data
- Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open-label randomized controlled study (the SMART study)
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02243176. Randomized; no masking; primary purpose treatment. Start 2014-09 (registry gives no type); primary completion 2015-09 (actual). Results posted on 2017-04-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy
- Acronym
- SMART
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Saxagliptin
- Intervention (Drug)
- Acarbose
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct02243176- Content hash
42f65be73281557d02ef04c7fb0adbdc17126f1378850dda9a251e75b456288c